Violet Kasabri - Search Results

Year	Number of Results
2009	1
2010	2
2011	4
2012	1
2013	1
2014	3
2015	1
2016	6
2017	7
2018	12
2019	7
2020	6
2021	0

1

Selected pharmacotherapy agents as antiproliferative and anti-inflammatory compounds.

AlKhalil M, Al-Hiari Y, Kasabri V, Arabiyat S, Al-Zweiri M, Mamdooh N, Telfah A. AlKhalil M, et al. Among authors: kasabri v. Drug Dev Res. 2020 Jun;81(4):470-490. doi: 10.1002/ddr.21640. Epub 2020 Jan 14. Drug Dev Res. 2020. PMID: 31943302

2

The use of medicinal herbs in gynecological and pregnancy-related disorders by Jordanian women: a review of folkloric practice vs. evidence-based pharmacology.

Akour A, Kasabri V, Afifi FU, Bulatova N. Akour A, et al. Among authors: kasabri v. Pharm Biol. 2016 Sep;54(9):1901-18. doi: 10.3109/13880209.2015.1113994. Epub 2016 Feb 25. Pharm Biol. 2016. PMID: 26911517 Review.

3

Hypothesis: Oxytocin is a direct COVID-19 antiviral.

Diep PT, Talash K, Kasabri V. Diep PT, et al. Among authors: kasabri v. Med Hypotheses. 2020 Dec;145:110329. doi: 10.1016/j.mehy.2020.110329. Epub 2020 Oct 1. Med Hypotheses. 2020. PMID: 33032171 Free PMC article. No abstract available.

4

Prevalence of Cardiovascular Diseases Risk Factors among Jordanians.

Alsaud W, Tabbaa MJ, Kasabri VN, Suyagh MF, Abu Alsamen MA, Haddad HM, ALshweki AO. Alsaud W, et al. Among authors: kasabri vn. J Saudi Heart Assoc. 2020 Aug 3;32(2):324-333. doi: 10.37616/2212-5043.1074. eCollection 2020. J Saudi Heart Assoc. 2020. PMID: 33154938 Free PMC article.

5

Pancreatic lipase inhibitory activity of selected pharmaceutical agents.

Hamdan II, Kasabri VN, Al-Hiari YM, El-Sabawi D, Zalloum H. Hamdan II, et al. Among authors: kasabri vn. Acta Pharm. 2019 Mar 1;69(1):1-16. doi: 10.2478/acph-2019-0010. Acta Pharm. 2019. PMID: 31259721

6

Proportional correlates of adipolin and cathepsin S in metabolic syndrome patients with and without prediabetes.

Kasabri V, Al-Ghareeb MI, Saleh MI, Suyagh M, Halaseh L, Al-Sarraf I, AlAlawi S. Kasabri V, et al. Diabetes Metab Syndr. 2019 Jul-Aug;13(4):2403-2408. doi: 10.1016/j.dsx.2019.06.010. Epub 2019 Jun 11. Diabetes Metab Syndr. 2019. PMID: 31405651

7

Correlates of resistin and retinol-binding protein 4 in metabolic syndrome patients with and without prediabetes.

Horan AA, Albsoul-Younes A, Kasabri V, Suyagh M, Halaseh L, AlAlawi S. Horan AA, et al. Among authors: kasabri v. Horm Mol Biol Clin Investig. 2019 Jan 23;37(3):/j/hmbci.2019.37.issue-3/hmbci-2018-0051/hmbci-2018-0051.xml. doi: 10.1515/hmbci-2018-0051. Horm Mol Biol Clin Investig. 2019. PMID: 30667366

8

Dual Glycation-Inflammation Modulation, DPP-IV and Pancraetic Lipase Inhibitory Potentials and Antiproliferative Activity of Novel Fluoroquinolones.

Arabiyat S, Kasabri V, Al-Hiari Y, Al-Masri I, Alalawi S, Bustanji Y. Arabiyat S, et al. Among authors: kasabri v. Asian Pac J Cancer Prev. 2019 Aug 1;20(8):2503-2514. doi: 10.31557/APJCP.2019.20.8.2503. Asian Pac J Cancer Prev. 2019. PMID: 31450926 Free PMC article.

9

The Evaluation of Potential Cytotoxic Effect of Different Proton Pump Inhibitors on Different Human Cancer Cell Lines.

Qasem A, Kasabri V, AbuRish E, Bustanji Y, Al-Hiari Y, Al-Abbasi R, Abu-Irmaileh B, Alalawi S. Qasem A, et al. Among authors: kasabri v. Anticancer Agents Med Chem. 2020;20(2):245-253. doi: 10.2174/1871520619666191029151545. Anticancer Agents Med Chem. 2020. PMID: 31663482

10

Development of a Thymoquinone Polymeric Anticancer Nanomedicine through Optimization of Polymer Molecular Weight and Nanoparticle Architecture.

Sunoqrot S, Alfaraj M, Hammad AM, Kasabri V, Shalabi D, Deeb AA, Hasan Ibrahim L, Shnewer K, Yousef I. Sunoqrot S, et al. Among authors: kasabri v. Pharmaceutics. 2020 Aug 27;12(9):811. doi: 10.3390/pharmaceutics12090811. Pharmaceutics. 2020. PMID: 32867015 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results